Ruth Beck, PA
Medical · Idaho Falls, IDNPI 1689749616
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 41.9% of the total. 2025 is the largest year on record at $539, 3.6 times the $149 reported in 2021.
Across 82 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$677
- Novo Nordisk$189
- Amgen$134
- AstraZeneca$90
- Insulet Corporation$82
- Boehringer Ingelheim$75
- plus $370 from 12 others
What the payments were for
- Food & beverage$1,615100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $677 |
| Novo Nordisk | 12 | $189 |
| Amgen | 7 | $134 |
| AstraZeneca | 6 | $90 |
| Insulet Corporation | 2 | $82 |
| Boehringer Ingelheim | 3 | $75 |
| GSK | 3 | $54 |
| Astellas Pharma US Inc | 2 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Johnson & Johnson | 2 | $38 |
| Boston Scientific | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Edwards Lifesciences | 1 | $19 |
| Bayer | 1 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
How this compares
$1,615 in reported general payments places this provider in the 80th percentile of 265 medical providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $39,060 |
| MounjaroTirzepatide | 35 | $36,472 |
| EliquisApixaban | 38 | $34,326 |
| FarxigaDapagliflozin Propanediol | 24 | $23,298 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,470 |
| JanuviaSitagliptin Phosphate | 11 | $12,967 |
| Nurtec OdtRimegepant Sulfate | 13 | $12,439 |
| TrulicityDulaglutide | 11 | $12,391 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,277 |
| MovantikNaloxegol Oxalate | 13 | $5,312 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 139 | $3,617 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,086 |
| Gabapentin | 153 | $2,779 |
| Levothyroxine Sodium | 294 | $2,433 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 56 | $2,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $14 | $48,86346 claims |
| Novo NordiskOzempic | $189 | $39,06031 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $54 | $32,83355 claims |
| AstraZenecaFarxiga | $90 | $23,29824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 medical providers in Idaho.
Other medical in Idaho Falls
- Jed BartschiIdaho Falls$11K
- Weldon RichardsonIdaho Falls$8K
- Wade ChristensenIdaho Falls$8K
- Joshua HansenIdaho Falls$8K
- Cameron FrenchIdaho Falls$5K
- Brandon LarsenIdaho Falls$5K
- Rebecca WestergardIdaho Falls$4K
- Shelley DavisIdaho Falls$4K
- Alyssa JenkinsIdaho Falls$3K
- William UlrichIdaho Falls$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.